Description
Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, antipyretic, neuroprotective, anticancer, and chemopreventive activities. Piroxicam inhibits COX-1 and COX-2. Cu(II) complexes of piroxicam bind GC sequences of DNA. In animal models, this compound decreases development of polyps and colorectal cancer. In cellular models of Parkinson’s disease, piroxicam inhibits MPP+-induced decreases in phosphorylated Akt and neurodegeneration.
References
Chakraborty S, Bose M, Sarkar M. Spectroscopic studies of the binding of Cu(II) complexes of oxicam NSAIDs to alternating G-C and homopolymeric G-C sequences. Spectrochim Acta A Mol Biomol Spectrosc. 2014 Mar 25;122:690-7. PMID: 24345609.
Barkin RL. Topical Nonsteroidal Anti-Inflammatory Drugs: The Importance of Drug, Delivery, and Therapeutic Outcome. Am J Ther. 2012 Feb 22. [Epub ahead of print]. PMID: 22367354.
Tasaki Y, Yamamoto J, Omura T, et al. Oxicam structure in non-steroidal anti-inflammatory drugs is essential to exhibit Akt-mediated neuroprotection against 1-methyl-4-phenyl pyridinium-induced cytotoxicity. Eur J Pharmacol. 2012 Feb 15;676(1-3):57-63. PMID: 22182582.
Qiu ZF, Maruyama K, Sunayama K, et al. Piroxicam-induced regression of intestinal adenomatous polyps in APC(delta474) mice. J Invest Surg. 2003 Mar-Apr;16(2):71-81. PMID: 12746190.